secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001619856-24-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences reports CB-010 ANTLER Phase 1 data: 14.4 mo median PFS with partial HLA matching
--------------------------------------------------------------------------------

- Median PFS of 14.4 months with ≥4 HLA matches (N=13) vs 2.8 months with ≤3 matches (N=33).
- In LBCL patients with ≥4 HLA matches (N=11), median PFS not reached; ORR 91%, CR rate 36%.
- No Grade ≥3 CRS or GvHD observed; RP2D selected at 80x10^6 CAR-T cells.
- Plan to enroll ~20 additional 2L LBCL patients prospectively; initial data expected H1 2025.
- Pivotal Phase 3 trial for CB-010 in 2L LBCL planned for H2 2025 if confirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/0001619856-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000046/crbu-20240602.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer